drugset / Trial / NCT00002586

13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer

NCT00002586

Phase 2 Completed 96 enrolled University of Colorado, Denver
RandomizedParallel-groupTriple-blindPrevention

Summary

RATIONALE: 13 Cis retinoic acid may prevent the development of cancer cells. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of 13-cis retinoic acid with or without vitamin E for chemoprevention or observation of cancer in persons at high risk of developing lung cancer.

Timeline

Start
1993-01
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Isotretinoin Other / unclassified 50 mg Oral
Subject Vitamin E Other / unclassified 800 mg Oral

Indications